Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781038 | 0.82 | ADORA3 (0.52) | TP53ALDH1A1NPSR1KDM4EHPGD | |
| SCHEMBL6228404 | 0.74 | TSHR (0.68) | TP53ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL9300374 | 0.74 | SMN1; SMN2 (0.65) | ALDH1A1HPGDTSHRMEN1KMT2A | |
| SCHEMBL29725680 | 0.70 | RAB9A (0.54) | TP53ALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL28768950 | 0.69 | ROCK1 (0.62) | ALDH1A1KDM4EHPGDTSHRMEN1 | |
| SCHEMBL6070369 | 0.69 | HPGD (0.75) | ALDH1A1NPSR1KDM4EHPGDPOLB | |
| SCHEMBL9396422 | 0.68 | PTGS2 (0.45) | ALDH1A1KDM4EHPGDTSHRPTGS2 | |
| SCHEMBL5958993 | 0.68 | PRKCI (0.59) | TP53ALDH1A1KDM4ETSHRPOLB | |
| SCHEMBL19382960 | 0.66 | L3MBTL1 (0.60) | TSHRPOLBMAPTMEN1KMT2A | |
| SCHEMBL2860286 | 0.66 | RAB9A (0.87) | HPGDPOLBMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | NYSNOBIO IRELAND DAC (IE) | 2021-08-12 | — | — | US | disclosed |
| US-20210230126-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2021-07-29 | — | — | US | disclosed |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | NYSNOBIO IRELAND DAC (IE) | 2021-01-12 | — | — | US | disclosed |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | NYSNOBIO IRELAND DAC (IE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244712-A1 | METHODS FOR TREATING PATIENTS WITH CANCER HAVING DEFECTS IN CYCLIN D REGULATION | TP53, RB1, CDK1 | TP53 1/4885ALDH1A1 2116/4885NPSR1 4488/4885 |
| US-20200172497-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | TP53 264/4885ALDH1A1 636/4885NPSR1 4446/4885 |
| US-20210230126-A1 | ASYMMETRIC TRIAZOLE BENZAMIDE DERIVATIVES AND THE COMPOSITIONS AND METHODS OF TREATMENT REGARDING THE SAME | ATG7, PINK1, ADRM1 | TP53 264/4885ALDH1A1 636/4885NPSR1 4446/4885 |
| US-10889553-B2 | Asymmetric triazole benzamide derivatives and the compositions and methods of treatment regarding the same | ATG7, PINK1, ADRM1 | TP53 264/4885ALDH1A1 636/4885NPSR1 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.